Read by QxMD icon Read


Xinchi Hou, Bozena Birkenfeld, Hanna Piwowarska-Bilska, Anna Celler
BACKGROUND: Technetium-99m-hydrazinonicotinamide-Tyr(3)-octreotide ((99m)Tc-HYNIC-TOC) is recognized as a promising radiopharmaceutical for diagnosing neuroendocrine tumors (NETs). However, (99m)Tc-HYNIC-TOC dosimetry has been investigated only for adults. As pediatric radionuclide therapies become increasingly common, similar dosimetric studies for children are urgently needed. The aim of this study is to report personalized image-based biodistributions and dosimetry evaluations for children studies performed using (99m)Tc-HYNIC-TOC and to compare them with those from adult subjects...
October 13, 2017: EJNMMI Physics
Richard P Baum, Aviral Singh, Christiane Schuchardt, Harshad Rajaram Kulkarni, Ingo Klette, Stefan Wiessalla, Frank Osterkamp, Ulrich Reineke, Christiane Smerling
Neurotensin receptor 1 (NTR1) is overexpressed in ductal pancreatic adenocarcinoma, which is still one of the deadliest cancers with a very poor prognosis. Eligible patients were offered radiopharmaceutical treatment with the novel NTR1 antagonist (177)Lu-3BP-227 as salvage therapy. Methods: Six patients with confirmed ductal pancreatic adenocarcinoma who had exhausted all other treatment options received (177)Lu-3BP-227 for evaluation of NTR1 expression in vivo. Three patients received treatment activities between 5...
October 12, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Carol Silber Marcus
The purpose of this article is to reconsider the manner in which the U.S. Food and Drug Administration (FDA) reviews diagnostic radiopharmaceuticals. Mass characteristics of several common non-radioactive drugs and a number of diagnostic radiopharmaceuticals are considered. A history of the regulation of radiopharmaceuticals is presented. Conclusion: The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American College of Nuclear Medicine (ACNM) should choose the membership of a Radiopharmaceutical Advisory Committee (RAC), and the FDA should contract with them to do so...
October 12, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Xiaoqing Song, Yue Wang, Junbo Zhang, Zhonghui Jin, Weifang Zhang, Yanyan Zhang
Currently, a popular strategy for designing novel radioprobes as bone imaging agents is based on the concept of bifunctional radiopharmaceticals. Considering the dithiocarbamate ligand can act as a suitable bifunctional linking agent to attach technetium-99m ((99m) Tc) to corresponding target molecules, in this study, alendronate dithiocarbamate (ALNDTC) was synthesized and radiolabeled with [(99m) Tc≡N](2+) core by ligand-exchange reaction to produce (99m) TcN-ALNDTC complex, for the potential use as a novel probe for bone imaging...
October 10, 2017: Chemical Biology & Drug Design
Michael S Hofman, Peter Eu, Price Jackson, Emily Hong, David Binns, Amir Iravani, Declan Murphy, Catherine Mitchell, Shankar Siva, Rodney J Hicks, Jennifer D Young, Philip Blower, Gregory E Mullen
Objectives: Ga-68 labelled urea-based inhibitors of the prostate-specific membrane antigen (PSMA), such as (68)Ga-HBED-PSMA-11, are promising small molecules for targeting prostate cancer. A new radiopharmaceutical (68)Ga-THP-PSMA has a simplified design for one-step kit-based radiolabelling. It features the tris(hydroxypyridinone) (THP) ligand, which complexes (68)Ga3+ rapidly at low concentration, room temperature and over a wide pH range, enabling direct elution from a (68)Ge/(68)Ga generator into a lyophilized kit in one-step without manipulation...
October 6, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
Michael S Gossman, Huaiyu Zheng, John G Evans, Junling Li, Chin K Ng
PURPOSE: The purpose of this study was to resolve the issue of whether various generations of CR Bard peripheral vascular access ports and catheters are prone to retain PET radiopharmaceuticals. The study evaluates the residual radioactivity remaining following injection for two PET radiopharmaceuticals currently used extensively in the clinic, FDG and Na(18) F. METHODS: FDG was purchased from a local cyclotron facility and Na(18) F was prepared in-house. Three generations of currently marketed vascular access ports were tested...
October 5, 2017: Journal of Applied Clinical Medical Physics
Seyed Javad Khoramrouz, Mostafa Erfani, Mitra Athari Allaf
Nuclear medicine imaging has been used to localize infection sites, and efforts have been continued to develop modified infection specific radiopharmaceuticals. In this study gemifloxacin as a broad-spectrum quinolone has been labeled with [(99m)Tc (CO)3 (H2O)3](+) core in order to evaluate its feasibility as an infection imaging agent for in-vivo use. The stability of radioconjugate was checked in human serum at 37 °C and biodistribution was studied in mice. Labeling yield of > 95% was obtained corresponding to a specific activity of 0...
2017: Iranian Journal of Pharmaceutical Research: IJPR
Siyavash Rahmani, Soraya Shahhoseini, Reza Mohamadi, Mostafa Vojdani
The introduction of 2-[(18)F] fluor-2-deoxy-D-glucose ((18)FDG) has provided a valuable tool for the study of glucose metabolism in both normal and diseased tissue in conjunction with positron emission tomography (PET). (18)FDG is the most important radiopharmaceutical to be used in Nuclear Medicine for studying the brain, heart and tumor. The advancement in synthesis and quality control of (18)FDG and its approval by US FDA are main reasons for increasing clinical application of (18)FDG over the last 20 years...
2017: Iranian Journal of Pharmaceutical Research: IJPR
İsa Burak Güney, Semra Paydaş, Hüseyin Tuğsan Ballı
Super scan is a well-known finding described in skeletal scintigraphy characterized by uniform symmetrically increased radiopharmaceutical uptake by bones and consequently diminished renal parenchymal activity. Sy et al. hypothesized that the faint visualization of renal cortex in bone scintigraphy might be the result of increased uptake of radiopharmaceutical by pathologic bones and reduced phosphate excretion. The super scan on (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT) has been observed in various conditions such as prostate cancer, lung cancer, renal adenocarcinoma, gastric cancer and primitive neuroectodermal tumor of the kidney...
October 3, 2017: Molecular Imaging and Radionuclide Therapy
Yong Du, Sabina Dizdarevic
Two different molecular radio-theragnostic principles are applied in prostate cancer, providing a personalised management for those patients. Firstly, radiopharmaceuticals with the same or similar mechanism of action but different energy (gamma-γ, eg (99m)Tc-diphosphonates or positron-β+, eg 18F-NaF emitting isotopes) can be used to identify patients with osteoblastic metastases for a treatment with bone seeking beta (β-) or alpha (α-) emitting radionuclides to deliver targeted molecular radiotherapy. A number of such β- emitting molecules have been used for bone palliation...
October 2017: Clinical Medicine: Journal of the Royal College of Physicians of London
Nitasha Singh, Val Lewington
Molecular radiotheragnostics directly links nuclear medicine diagnostic imaging to therapy. The imaging study is used to detect a specific molecular target associated with a disease process. A radiotherapeutic molecule with a similar biodistribution to the diagnostic agent can then be used to deliver targeted therapy.Molecular radiotheragnostics have been applied to manage both benign and malignant thyroid disease since the 1940s. The specific molecular pathway targeted is the sodium/iodide symporter (NIS) located on the basolateral membrane of the thyroid follicular cell...
October 2017: Clinical Medicine: Journal of the Royal College of Physicians of London
Maurizio Dondi, Leonel Torres, Mario Marengo, Teresa Massardo, Eyal Mishani, Annare Van Zyl Ellmann, Kishor Solanki, Angelika Bischof Delaloye, Enrique Estrada Lobato, Rodolfo Nunez Miller, Felix Barajas Ordonez, Diana Paez, Thomas Pascual
The International Atomic Energy Agency has developed a program, named Quality Management Audits in Nuclear Medicine (QUANUM), to help its Member States to check the status of their nuclear medicine practices and their adherence to international reference standards, covering all aspects of nuclear medicine, including quality assurance/quality control of instrumentation, radiopharmacy (further subdivided into levels 1, 2, and 3, according to complexity of work), radiation safety, clinical applications, as well as managerial aspects...
November 2017: Seminars in Nuclear Medicine
Maurizio Dondi, Leonel Torres, Mario Marengo, Teresa Massardo, Eyal Mishani, Annare Van Zyl Ellmann, Kishor Solanki, Angelika Bischof Delaloye, Enrique Estrada Lobato, Rodolfo Nunez Miller, Diana Paez, Thomas Pascual
An effective management system that integrates quality management is essential for a modern nuclear medicine practice. The Nuclear Medicine and Diagnostic Imaging Section of the International Atomic Energy Agency (IAEA) has the mission of supporting nuclear medicine practice in low- and middle-income countries and of helping them introduce it in their health-care system, when not yet present. The experience gathered over several years has shown diversified levels of development and varying degrees of quality of practice, among others because of limited professional networking and limited or no opportunities for exchange of experiences...
November 2017: Seminars in Nuclear Medicine
Christopher J Palestro, Charito Love
Infection is an infrequent complication of lower extremity prosthetic joint surgery. Approximately one-third develop within 3 months (early), another third within 1 year (delayed), and the remainder more than 1 year (late) after surgery. Diagnosing prosthetic joint infection, especially in the early postoperative period during the first year, is challenging. Pain is almost always present. The presence of fever is variable, ranging from less than 5% to more than 40% of patients. Leukocytosis is a poor predictor of infection...
November 2017: Seminars in Nuclear Medicine
Zhide Guo, Linyi You, Changrong Shi, Manli Song, Mengna Gao, Duo Xu, Chenyu Peng, Rongqiang Zhuang, Ting Liu, Xinhui Su, Jin Du, Xianzhong Zhang
This study aims to develop a new folate receptor (FR)-targeting agent for SPECT imaging with improved contrast and evaluate the modification strategies of multimerization and/or PEGylation in the development of new radio-folates. A series of novel folate derivatives have been synthesized and radiolabeled with (99m)Tc using tricine and TPPTS as coligands. To better investigate their pharmacokinetics, cell uptake, biodistribution, and microSPECT/CT imaging were evaluated. Four radioligands displayed high KB cell uptake after incubation for 2 and 4 h...
October 12, 2017: Molecular Pharmaceutics
Daphnée Villoing, Vladimir Drozdovitch, Steven L Simon, Cari M Kitahara, Martha S Linet, Dunstana R Melo
Ionizing radiation exposure to the general U.S. population nearly doubled between 1980 and 2006, due almost entirely to the significant increase in the number of radiologic and nuclear medicine procedures performed. Significant changes in the types of procedures and radionuclides used in nuclear medicine, as well as in detection technology, have led to notable changes over time in absorbed doses to specific organs. This study is the first to estimate per-procedure organ doses to nuclear medicine patients and trends in doses over five decades...
September 29, 2017: Health Physics
Nishant Gupta, Arushi Devgan, Itisha Bansal, Thomas D Olsavsky, Shuo Li, Ahmed Abdelbaki, Yogesh Kumar
Castration-resistant prostate osseous metastases can be challenging to treat. There is a new era of clinical advancement with the Food and Drug Administration approval of radium-223 for use in these patients. Radium-223 is the only clinically used therapeutic radiopharmaceutical that emits alpha particles, making it extremely safe for therapeutic purposes for the patient as well as close contacts. This review discusses radium-223's mechanism of action, pharmacokinetics, indications, and safety profile, as well as findings of concluded clinical trials...
October 2017: Proceedings of the Baylor University Medical Center
Daiko Matsuoka, Hiroyuki Watanabe, Yoichi Shimizu, Hiroyuki Kimura, Masahiro Ono, Hideo Saji
Prostate-specific membrane antigen (PSMA), which is highly expressed in both localized and metastatic prostate cancer (PCa), is an ideal target for imaging and therapy of PCa. We previously reported radiolabeled asymmetric urea derivatives asa PSMA-targeting radiotracer for single-photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging. Here, based on these radiopharmaceutical probes, we designed a novel near-infrared (NIR) fluorescent imaging probe (800CW-SCE) by chemical conjugation between IRDye 800CW-Maleimide and an asymmetric urea compound, known as PSMA inhibitor, for optical imaging...
September 18, 2017: Bioorganic & Medicinal Chemistry Letters
Jens Cardinale, René Martin, Yvonne Remde, Martin Schäfer, Antje Hienzsch, Sandra Hübner, Anna-Maria Zerges, Heike Marx, Ronny Hesse, Klaus Weber, Rene Smits, Alexander Hoepping, Marco Müller, Oliver C Neels, Klaus Kopka
Radiolabeled tracers targeting the prostate-specific membrane antigen (PSMA) have become important radiopharmaceuticals for the PET-imaging of prostate cancer. In this connection, we recently developed the fluorine-18-labelled PSMA-ligand [(18)F]PSMA-1007 as the next generation radiofluorinated Glu-ureido PSMA inhibitor after [(18)F]DCFPyL and [(18)F]DCFBC. Since radiosynthesis so far has been suffering from rather poor yields, novel procedures for the automated radiosyntheses of [(18)F]PSMA-1007 have been developed...
September 27, 2017: Pharmaceuticals
Blanca E Ocampo-García, Clara L Santos-Cuevas, Myrna A Luna-Gutiérrez, Eleazar Ignacio-Alvarez, Martha Pedraza-López, Cesar Manzano-Mayoral
AIM: About 90% of insulinomas are benign and 5-15% are malignant. Benign insulinomas express the glucagon-like peptide-1 receptor (GLP-1R, which recognizes exendin-4 and low levels of the somatostatin receptor (SSTR, which recognizes octreotide), whereas malignant insulinomas overexpress SSTR and low levels of GLP-1R. Recently, Lys(Tc-EDDA/HYNIC)-exendin(9-39)/Tc-EDDA/HYNIC-Tyr-octreotide was formulated to detect 100% of insulinomas. The aim of this study was to estimate the biokinetics and dosimetry of Tc-exendin(9-39)/octreotide in four healthy individuals...
September 25, 2017: Nuclear Medicine Communications
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"